Dateline City:
VIENNA
Data Sets Include Treatment-Nave, Treatment-Experienced and HIV Co-Infected Patients with Chronic Hepatitis C Virus Genotypes 1, 4 or 6 Infection
Merck Remains on Track to Submit New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) in First Half of 2015
VIENNA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first presentations of data from the companys
ongoing C-EDGE pivotal Phase 3 clinical trial program evaluating
the investigational once-daily tablet grazoprevir/elbasvir (100mg/50mg)
in patients with or without cirrhosis who are infected with chronic
hepatitis C virus (HCV) genotypes 1, 4 or 6 (GT1, 4 or 6).1
Patients in both the HCV infected, treatment-nave (C-EDGE TN),
and HIV/HCV co-infected, treatment-nave (C-EDGE CO-INFXN